{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:57:36Z","timestamp":1792897056620,"version":"4.5.0"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurg.","NEUROS"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The BRAF mutation has been identified as a potent target for the treatment of metastatic melanoma and BRAF inhibitors (BRAFi) have demonstrated promising results against melanoma brain metastases (BM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To further investigate the effectiveness of this combined treatment regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>In this multicenter retrospective cohort study, 198 patients with known BRAF mutation status and treated with stereotactic radiosurgery (SRS) between 2011 and 2015 were identified. Kaplan\u2013Meier methodology and multivariate regression analysis was then used to compare survival based on each parameter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The median survival after the diagnosis of BM in patients with BRAF mutation who received BRAFi was increased compared to survival in patients with wild-type BRAF (BRAF wt). In multivariate analysis, the BRAF mutation was an independent, positive prognostic factor with a hazard ratio of 0.59. BRAF mutated Patients who received BRAFi following SRS had improved survival compared to patients who received it before (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0&lt;\u00a0.001) or concurrently (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a0.007). PD-1 inhibitors improved survival, with more pronounced effect in patients not carrying the BRAF mutation. Among the patients who were treated with BRAFi, 10.4% developed intracerebral hematoma (ICH), in comparison to 3% of patients who were not treated with BRAFi (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u00a0=\u00a0.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In the setting of widespread use of BRAFi, the presence of a BRAF mutation is an independent predictor of better prognosis in patients with melanoma BM that underwent SRS. The effect of BRAFi is optimal when treatment is initiated at least 1 wk following SRS. BRAFi may increase the frequency of asymptomatic ICH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuros\/nyy203","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T02:51:41Z","timestamp":1524019901000},"page":"868-880","source":"Crossref","is-referenced-by-count":31,"title":["BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study"],"prefix":"10.1227","volume":"84","author":[{"given":"Panagiotis","family":"Mastorakos","sequence":"first","affiliation":[{"name":"Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia"},{"name":"Department of Neurological Surgery, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Chatrath","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis G","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Kondziolka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Warnick","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Chiang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sheehan","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia"},{"name":"Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,4]]},"reference":[{"issue":"8","key":"bib1-20231011","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2174\/15680096113139990080","article-title":"Ipilimumab and vemurafenib: two different routes for targeting melanoma","volume":"13","author":"Burgeiro","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"bib2-20231011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-1654","article-title":"Ipilimumab in melanoma patients with brain metastasis: a retro\u00adspective multicentre evaluation of thirty-eight patients","volume":"94","author":"Konstantinou","year":"2014","journal-title":"Acta Derm Venerol"},{"issue":"11","key":"bib3-20231011","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"bib4-20231011","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"bib5-20231011","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2011.38.0527","article-title":"Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases","volume":"30","author":"Sperduto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"bib6-20231011","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3171\/jns.2002.96.3.0544","article-title":"Gamma surgery for melanoma metastases in the brain","volume":"96","author":"Mingione","year":"2002","journal-title":"J Neurosurg"},{"issue":"5","key":"bib7-20231011","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1001\/jamaoncol.2015.1206","article-title":"Clinical management of multiple melanoma brain metastases","volume":"1","author":"Goyal","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"bib8-20231011","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"issue":"6892","key":"bib9-20231011","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"35","key":"bib10-20231011","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1200\/JCO.2008.17.5448","article-title":"Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group","volume":"26","author":"Atkins","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"bib11-20231011","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"issue":"9839","key":"bib12-20231011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet North Am Ed"},{"issue":"26","key":"bib13-20231011","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"bib14-20231011","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"9829","key":"bib15-20231011","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet North Am Ed"},{"issue":"4","key":"bib16-20231011","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CMR.0000000000000068","article-title":"Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases","volume":"24","author":"Dzienis","year":"2014","journal-title":"Melanoma Res"},{"issue":"7","key":"bib17-20231011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/theoncologist.2014-0012","article-title":"A Retrospective evaluation of vemurafenib as treatment for BRAF-Mutant melanoma brain metastases","volume":"20","author":"Harding","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"bib18-20231011","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s11060-016-2072-6","article-title":"Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases","volume":"127","author":"Wolf","year":"2016","journal-title":"J Neurooncol"},{"key":"bib19-20231011","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3171\/2016.2.JNS1633","article-title":"BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases","volume":"126(3)","author":"Xu","year":"2017","journal-title":"J Neurosurg"},{"issue":"1","key":"bib20-20231011","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3171\/jns.2006.104.1.157","article-title":"Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error","volume":"104","author":"Snell","year":"2006","journal-title":"J Neurosurg"},{"issue":"9","key":"bib21-20231011","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-08-2954","article-title":"In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase 1\/2 kinase","volume":"15","author":"Chung","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"bib22-20231011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","article-title":"Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032","volume":"98","author":"Sambade","year":"2011","journal-title":"Radiother Oncol"},{"issue":"6","key":"bib23-20231011","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy\u2013mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"bib24-20231011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","article-title":"Vemurafenib and radiation therapy in melanoma brain metastases","volume":"113","author":"Narayana","year":"2013","journal-title":"J Neurooncol"},{"issue":"4","key":"bib25-20231011","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"issue":"2","key":"bib26-20231011","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3171\/2014.9.JNS141425","article-title":"Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment","volume":"123","author":"Ly","year":"2015","journal-title":"J Neurosurg"},{"key":"bib27-20231011","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.2147\/OTT.S119428","article-title":"BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy","volume":"9","author":"Chowdhary","year":"2016","journal-title":"OTT"},{"issue":"2","key":"bib28-20231011","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molonc.2011.01.005","article-title":"Biological challenges of BRAF inhibitor therapy","volume":"5","author":"Puzanov","year":"2011","journal-title":"Mol Oncol"},{"issue":"6","key":"bib29-20231011","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"issue":"10","key":"bib30-20231011","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"bib31-20231011","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10552-014-0443-x","article-title":"Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma","volume":"25","author":"Wu","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"15","key":"bib32-20231011","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ejca.2014.06.009","article-title":"BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy","volume":"50","author":"Barbour","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"bib33-20231011","doi-asserted-by":"crossref","first-page":"e25806","DOI":"10.1371\/journal.pone.0025806","article-title":"BRAF mutations in advanced cancers: clinical characteristics and outcomes","volume":"6","author":"El-Osta","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"bib34-20231011","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.ijrobp.2013.06.717","article-title":"Influence of BRAF and NRAS mutations on distant intracranial recurrence and survival in metastatic melanoma following radiosurgery","volume":"872","author":"Rutter CE","year":"2013","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"15_suppl","key":"bib35-20231011","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1200\/jco.2012.30.15_suppl.8584","article-title":"Correlation of BRAF and NRAS mutation status with tumor characteristics and treatment outcomes in melanoma patients with brain metastasis","volume":"30","author":"Eugene Jon Koay","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"bib36-20231011","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/2159-8290.CD-12-0313","article-title":"Elucidating distinct roles for NF1 in melanomagenesis","volume":"3","author":"Maertens","year":"2013","journal-title":"Cancer Discov"},{"issue":"8","key":"bib37-20231011","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"bib38-20231011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"bib39-20231011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaFV600E inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"bib40-20231011","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.114.058339","article-title":"Factors influencing the CNS distribution of a novel MEK-1\/2 Inhibitor: Implications for combination therapy for melanoma brain metastases","volume":"42","author":"Vaidhyanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"bib41-20231011","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"issue":"24","key":"bib42-20231011","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"JNCI J Nat Cancer Inst"},{"issue":"2","key":"bib43-20231011","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"4","key":"bib44-20231011","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.molonc.2008.01.002","article-title":"Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas","volume":"1","author":"Kannengiesser","year":"2008","journal-title":"Mol Oncol"},{"issue":"13","key":"bib45-20231011","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1158\/1078-0432.CCR-09-2509","article-title":"Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome","volume":"16","author":"Jonsson","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"23","key":"bib46-20231011","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1038\/sj.onc.1207563","article-title":"Microarray expression profiling in melanoma reveals a BRAF mutation signature","volume":"23","author":"Pavey","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"bib47-20231011","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000044","article-title":"Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib","volume":"24","author":"Liebner","year":"2014","journal-title":"Melanoma Res"},{"issue":"17","key":"bib48-20231011","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","article-title":"Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma","volume":"31","author":"Anker","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"bib49-20231011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","article-title":"Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib","volume":"190","author":"Schulze","year":"2014","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"bib50-20231011","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00066-014-0707-0","article-title":"Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia","volume":"190","author":"Lang","year":"2014","journal-title":"Strahlenther Onkol"},{"issue":"14","key":"bib51-20231011","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"bib52-20231011","doi-asserted-by":"crossref","DOI":"10.3171\/2017.7.JNS171286","article-title":"Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects","author":"Diao","year":"2018","journal-title":"J Neurosurg"},{"issue":"3","key":"bib53-20231011","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"bib54-20231011","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF\u2013MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"issue":"19","key":"bib55-20231011","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"bib56-20231011","doi-asserted-by":"crossref","first-page":"e22890","DOI":"10.4161\/onci.22890","article-title":"Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells","volume":"2","author":"Sapkota","year":"2013","journal-title":"OncoImmunology"},{"issue":"19","key":"bib57-20231011","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2169\/internalmedicine.51.7675","article-title":"Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis","volume":"51","author":"Balakan","year":"2012","journal-title":"Intern Med"}],"container-title":["Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006123-201904000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:52:18Z","timestamp":1786121538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006123-201904000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1093\/neuros\/nyy203","relation":{},"ISSN":["0148-396X","1524-4040"],"issn-type":[{"value":"0148-396X","type":"print"},{"value":"1524-4040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]}}}